# DESCRIPTION

## TECHNICAL FIELD

- introduce antibodies and methods

## BACKGROUND

- discuss RSV and prior art

## SUMMARY

- introduce isolated polypeptides
- describe antibodies or antigen-binding fragments
- specify prophylaxis and treatment of RSV infection
- specify diagnosis and/or monitoring of RSV infection
- describe immunospecific binding to RSV
- describe neutralization of RSV
- specify binding to F protein
- describe neutralization of RSV subtypes A and B
- specify VH CDR1 sequences
- specify VH CDR2 sequences
- specify VH CDR3 sequences
- specify VL CDR1 sequences
- specify VL CDR2 sequences
- specify VL CDR3 sequences
- describe antibodies containing specific VH and VL domains
- describe immunospecific binding to same epitope on RSV fusion (F) protein
- specify additional VH and VL sequences
- describe additional antibodies containing specific VH and VL domains
- describe immunospecific binding to same epitope on RSV fusion (F) protein
- define isolated antibodies
- describe epitope binding
- specify VH and VL chains
- detail CDR sequences
- describe immunospecific binding
- introduce isolated polypeptides
- describe antigen-binding domains
- specify multivalent antibodies
- detail multimerization domains
- introduce combinations with antiviral agents
- describe combinations with additional antiviral antibodies
- specify antiviral antibody fragments
- introduce pharmaceutical compositions
- formulate pharmaceutical compositions
- provide additional antiviral antibodies
- provide antiviral agents
- treat viral infections
- administer pharmaceutical compositions
- specify subject and administration route
- provide methods of treating viral infections
- provide methods of detecting RSV infection
- provide isolated nucleic acids and vectors
- provide isolated cells and transgenic animals
- provide kits and instructions
- provide uses of antibodies or antigen-binding fragments

## DETAILED DESCRIPTION

### Outline

- outline anti-RSV antibodies
- describe methods and uses

### A. DEFINITIONS

- define terms used in the invention
- specify incorporation of references by reference
- define antibody
- define antibody fragments
- define therapeutic antibody
- define neutralizing antibody
- define enveloped virus
- define non-enveloped virus
- define surface protein
- define monoclonal antibody
- define conventional antibody
- define various antibody fragments (e.g. Fv, dsFv, Fd, Fab, F(ab′)2, Fab′, F
- define derivatives of anti-RSV antibodies
- define derived antibody fragments
- define parent antibody
- define epitope
- define chimeric polypeptide
- define fusion protein
- define linker or spacer peptide
- define antibody hinge region
- define diabodies
- define humanized antibodies
- define idiotype
- define anti-idiotype antibody
- define Ig domain
- define variable domain or variable region
- define antigen-binding domain
- define framework regions
- define functional regions of antibody domains
- define multivalent antibody
- define monospecific antibody
- define multispecific antibody
- define bispecific antibody
- define heterobivalent antibody
- define homobivalent antibody
- define multimerization domain
- define dimerization domains
- define Fc region
- define Fc chimera
- define protein transduction domain
- define native polypeptide and nucleic acid
- define wild-type form of polypeptide or nucleic acid
- define predominant form of polypeptide or nucleic acid
- define allelic variant and allelic variation
- define allele
- define species variants
- define polypeptide domain
- define functional region of polypeptide
- define structural region of polypeptide
- define property of polypeptide
- define activity of polypeptide
- define therapeutic activity
- define exhibits at least one activity
- define assessing activity
- define nucleic acid
- define polynucleotide and nucleic acid molecule
- define DNA construct
- define DNA segment
- define positive strand polynucleotide
- define genetic element
- define regulatory region of nucleic acid molecule
- define regulatory regions
- define operably linked
- define synthetic
- define production by recombinant means
- define expression
- define host cell
- define vector
- define expression vector
- define oligonucleotide
- define synthetic oligonucleotides
- define primer
- define primer pair
- define single primer
- define complementarity
- define complementary strand
- define specifically hybridizes
- define primary sequence
- define similarity
- define identity
- define identity of nucleic acid molecules
- describe determination of percent homology or identity
- explain alignment of sequences
- define analogous portions or positions
- describe modifications of sequences
- define deletion, insertion, and addition
- explain substitution of nucleotides or amino acids
- define binding property
- describe affinity and avidity
- explain binding of molecules
- define affinity constant
- describe substantially the same binding affinity
- explain having the same binding specificity
- describe competition assays
- define monoclonal antibody resistant mutant
- explain generation of MARMs
- describe EC50
- define binding partner
- explain selection of variant polypeptides
- describe in vitro selection methods
- define disulfide bond
- define coupled or conjugated
- define conjugated to an antibody
- define phage display
- define phage-display compatible cell
- define panning
- define display protein
- define coat protein
- define disease or disorder
- define infection and RSV infection
- define acute RSV disease
- define treating
- define prevention
- define pharmaceutically effective agent
- define therapeutic effect
- define therapeutically effective amount
- define prophylactically effective amount
- define immunotherapeutically
- define various other terms

### B. OVERVIEW

- introduce anti-RSV antibodies
- motivate prophylaxis therapies
- describe antibody applications
- discuss RSV persistence challenges
- highlight advantages of provided antibodies
- describe antibody binding properties
- discuss RSV infection and symptoms
- introduce RSV structure and proteins
- summarize existing anti-RSV antibodies
- discuss RSV mutations and escape mutants

### C. ANTI-RSV ANTIBODIES

- introduce anti-RSV antibodies
- describe general antibody structure
- explain functional domains of antibodies
- detail structural and functional domains
- describe antibody fragments
- explain generation of antigen-binding fragments
- introduce single chain antibodies
- describe exemplary anti-RSV antibodies
- introduce anti-RSV antibodies
- describe properties of anti-RSV antibodies
- provide examples of anti-RSV antibodies
- describe forms of anti-RSV antibodies
- describe uses of anti-RSV antibodies
- provide exemplary anti-RSV antibodies
- describe full-length antibody forms
- describe other antibody fragment forms
- provide examples of antibody fragments
- describe VH and VL domains
- provide examples of VH and VL domains
- describe identity of VH and VL domains
- provide examples of identity of VH and VL domains
- describe percentage identity of VH and VL domains
- provide examples of percentage identity of VH and VL domains
- define anti-RSV antibodies
- specify VH domain sequences
- specify VL domain sequences
- provide examples of VH CDR1 sequences
- provide examples of VH CDR2 sequences
- provide examples of VH CDR3 sequences
- describe particular examples of anti-RSV antibodies
- provide additional particular examples of anti-RSV antibodies
- provide further particular examples of anti-RSV antibodies
- define anti-RSV antibodies
- specify VH CDRs
- specify VL CDRs
- provide examples of anti-RSV antibodies
- describe framework regions
- define isolated anti-RSV antibodies
- specify epitopes of anti-RSV antibodies
- describe binding affinity constants
- describe dissociation constants
- describe EC50 values
- specify in vitro microneutralization assay
- specify in vitro plaque reduction assay
- describe anti-RSV antibodies
- neutralize monoclonal antibody escape mutants
- bind to epitope less susceptible to variation
- inhibit RSV replication
- have long half-life
- generate derivative antibodies
- produce chimeric antibodies
- graft CDRs onto heterologous framework
- substitute framework residues
- describe binding affinity and dissociation constants
- describe neutralization and inhibition of RSV
- introduce anti-RSV antibodies
- describe single chain antibodies
- motivate use of single chain antibodies
- describe generation of single chain antibodies
- describe structure of single chain antibodies
- introduce anti-idiotype antibodies
- describe generation of anti-idiotype antibodies
- introduce multi-specific antibodies and antibody multimerization
- describe generation of multi-specific antibodies
- describe structure of multi-specific antibodies
- list anti-RSV antibodies
- describe multispecific antibody structure
- introduce peptide linkers for multimerization
- describe multimerization via heterobifunctional linking agents
- list heterobifunctional cross-linking reagents
- introduce polypeptide multimerization domains
- describe multimerization domain structure
- describe chimeric polypeptide generation
- describe multimerization domain interaction
- describe multivalent antibody generation
- describe antigen-binding fragment conjugation
- describe chimeric polypeptide formation
- define multivalent antibody
- describe formation of multivalent antibodies
- introduce immunoglobulin domain
- describe structure of immunoglobulin molecule
- introduce Fc domain
- describe structure of Fc domain
- discuss use of Fc domain in multivalent antibodies
- describe modifications to Fc domain
- describe formation of bivalent antibodies
- describe purification of multivalent antibodies

### D. ADDITIONAL MODIFICATIONS OF ANTI-RSV ANTIBODIES

- introduce modifications of anti-RSV antibodies
- improve properties of antibodies
- modify primary amino acid sequence
- alter post-translational modification
- attach heterologous peptides for purification
- target antibodies to specific cell types
- attach diagnostic and/or therapeutic moieties
- covalently attach molecules to antibodies
- fuse antibodies to heterologous polypeptides
- generate fusion proteins through DNA shuffling
- attach antibodies to solid supports
- reduce immunogenicity of antibodies
- modify Fc region of antibodies
- alter effector functions of Fc region
- modify Fc region for optimized binding to FcγRs
- improve interaction with FcRn receptor
- modify Fc region to increase in vivo half-life
- modify Fc region to alter serum half-life
- describe modifications of anti-RSV antibodies
- motivate C1q binding enhancement
- describe Fc mutants with reduced FcγR binding
- introduce Fc fusion proteins
- describe pegylation of anti-RSV antibodies
- introduce conjugation of detectable moieties
- describe conjugation of therapeutic moieties
- introduce cytotoxins and therapeutic agents
- describe conjugation of therapeutic polypeptides
- motivate improvement of binding specificity
- introduce phage display methods
- describe selection of phage with antigen-binding domains
- introduce recombinant production of antibodies
- describe mutagenesis of CDRs for improved properties
- introduce human or chimeric antibodies for in vivo use

### E. METHODS OF ISOLATING ANTI-RSV ANTIBODIES

- introduce methods of isolating anti-RSV antibodies
- describe murine hybridomas
- describe transgenic mice expressing human immunoglobulin genes
- describe phage display
- describe isolation from mature human immune cells
- describe immortalization of human B cells with Epstein Barr Virus (EBV)
- describe cell fusion with myeloma cell line
- describe additional techniques for improving EBV immortalization
- describe isolation of human monoclonal antibodies from B cells
- describe selection of specific immune cells such as B cells
- describe use of antibodies that bind specifically to B-cell specific cell surface proteins
- describe selection of cell markers for purification
- describe stimulation of B cells using polyclonal activators
- describe use of stimulating agents such as CpG oligonucleotides and cytokines
- describe isotype-based selection of cells
- describe use of viral immortalization agents such as EBV and HHV-8
- describe recombinant DNA constructs for immortalization
- describe culturing of immortalized cells on feeder cell layers
- describe applications of immortalized cells, including antibody isolation and production

### F. METHODS OF PRODUCING ANTI-RSV ANTIBODIES, AND MODIFIED OR VARIANT FORMS THEREOF AND NUCLEIC ACIDS ENCODING ANTIBODIES

- generate anti-RSV antibodies
- describe host cells and vectors
- transform host cells with nucleic acids
- produce monoclonal antibodies
- express polypeptides in organisms
- introduce nucleic acids into expression hosts
- describe isolated nucleic acid molecules
- encode anti-RSV antibodies
- provide nucleic acid sequences
- modify antibodies using recombinant techniques
- insert CDRs into framework regions
- generate polynucleotides
- describe vectors containing nucleic acids
- provide expression vectors
- describe promoters and enhancers
- control expression of antibodies
- provide transcriptional and translational termination signals
- describe cell expression systems
- express nucleic acids in host cells
- introduce recombinant molecules into host cells
- introduce methods of producing anti-RSV antibodies
- transfect host cells with vectors encoding heavy and light chains
- describe expression vectors and host cells
- express proteins in prokaryotic cells
- describe expression in E. coli
- express proteins in yeast cells
- describe expression in yeast
- express proteins in insect cells
- describe expression in insect cells using baculovirus
- express proteins in mammalian cells
- describe expression in mammalian cells
- express proteins in plants
- describe expression in plants
- purify antibodies from host cells
- describe purification methods
- analyze isolated polypeptides
- assess binding of isolated polypeptides

### G. ASSESSING ANTI-RSV ANTIBODY PROPERTIES AND ACTIVITIES

- introduce anti-RSV antibody characterization
- motivate binding assays
- describe binding assays
- summarize immunoassay formats
- detail immunoprecipitation protocols
- explain western blot analysis
- describe ELISAs
- motivate competitive binding assays
- describe radioimmunoassays
- explain surface plasmon resonance kinetic analysis
- motivate inhibition of RSV binding to host cell receptor
- describe cell-free assays
- introduce binding specificity
- motivate epitope determination
- describe competition assays
- explain virus neutralization assays using MARMs
- summarize epitope determination using MARMs
- describe in vitro assays for analyzing virus neutralization effects of antibodies
- introduce plaque assays
- describe plaque reduction assays
- describe plaque size reduction assays
- describe virus neutralization assays
- describe assays for inhibition of syncytium formation
- describe in vivo animal models for assessing efficacy of anti-RSV antibodies
- describe in vitro and in vivo assays for measuring antibody efficacy
- describe testing anti-RSV antibodies for inducing cytokine expression
- describe testing anti-RSV antibodies for modulating immune cell activity
- describe testing anti-RSV antibodies for inhibiting viral replication

### H. DIAGNOSTIC USES

- introduce diagnostic assays
- describe in vitro detection of RSV
- motivate conjugation to detectable moiety
- describe in vitro detection methods
- summarize immobilization techniques
- describe competitive assay
- introduce solid support materials
- describe immobilization of anti-RSV antibody
- introduce flow-through or strip test format
- describe in vivo detection of pathogenic infection
- motivate imaging agent selection
- describe attachment methods for imaging agents
- introduce radioisotopes for in vivo diagnosis
- describe monitoring infection
- motivate diagnostic uses
- describe subjects for therapy
- identify subjects at risk of RSV infection
- describe administration of anti-RSV antibodies
- discuss maintenance or suppression therapy
- describe administration to subjects at risk
- discuss tests for pathogens and pathogenic infection
- describe administration during RSV season
- define dosages
- determine therapeutically effective concentration
- discuss factors affecting dosage
- describe exemplary dosages
- discuss serum titer
- describe administration by pulmonary delivery
- discuss titer in intubation sample, sputum or lavage
- describe repeated administrations
- discuss dosage regimens
- describe administration sequence
- discuss prophylactic administration
- describe therapeutic efficacy assessment
- discuss routes of administration
- describe pulmonary delivery methods
- describe diagnostic uses of anti-RSV antibodies
- list administration routes for anti-RSV antibodies
- introduce combination therapies for RSV infection
- describe co-administration of anti-RSV antibodies with therapeutic agents
- outline administration timing and frequency for combination therapies
- provide efficacy data for combination therapies
- list additional agents for combination therapies
- describe therapies for RSV infection prevention and treatment
- introduce antiviral agents for combination therapies
- list exemplary antiviral agents for combination therapies
- describe immunostimulatory agents for combination therapies
- outline dosages for combination therapies
- provide references for combination therapies
- introduce antiviral antibodies for combination therapy
- describe additional antibodies for combination therapy
- specify antiviral antibodies that bind to viral antigens
- describe antibodies that bind to RSV antigens
- specify antibodies that bind to RSV F protein
- list exemplary anti-RSV antibodies for combination therapy
- describe antibodies containing VH and/or VL chains
- specify antibodies containing CDRs of anti-RSV antibodies
- describe antibodies containing VH chains with specific sequences
- describe antibodies containing VH domains with specific sequences
- specify antibodies containing VH CDR1 with specific sequences
- specify antibodies containing VH CDR2 with specific sequences
- specify antibodies containing VH CDR3 with specific sequences
- describe antibodies containing VL chains with specific sequences
- describe antibodies containing VL domains with specific sequences
- specify antibodies containing VL CDR1 with specific sequences
- specify antibodies containing VL CDR2 and VL CDR3 with specific sequences
- introduce diagnostic uses
- describe antibodies against other respiratory viruses
- specify anti-PIV antibodies
- specify anti-hMPV antibodies
- describe types of antibodies administered
- describe effects of antibody administration
- describe inhibition of RSV binding and replication
- introduce gene therapy
- describe methods of gene therapy
- describe expression vectors
- describe delivery of nucleic acids
- describe viral vectors
- describe adenovirus vectors
- describe adeno-associated virus vectors
- describe introduction of nucleic acids into cells
- describe administration of recombinant cells
- describe cells used for gene therapy
- introduce pharmaceutical compositions
- describe formulation of pharmaceutical compositions
- describe presentation of pharmaceutical compositions
- define pharmaceutical compositions
- list pharmaceutical carriers and additives
- describe stabilization agents
- outline dosage forms
- discuss lyophilization and reconstitution
- describe controlled release compositions
- list polymers for sustained release formulations
- outline additional antibodies for pharmaceutical compositions
- list exemplary anti-RSV antibodies
- describe articles of manufacture/kits
- outline packaging materials
- describe kit components
- outline instructions for kits
- describe diagnostic kits
- outline devices for administering anti-RSV antibodies
- describe combinations of anti-RSV antibodies and second agents
- introduce examples of RSV F protein expression
- capture with anti-RSV mAb
- motivate example 2
- introduce EBV-transformed B cells
- describe procedure A for generating and cloning EBV-transformed B cells
- describe B cell cloning
- screen B cell supernatant for binding to RSV F protein
- introduce procedure B for generating and cloning EBV-transformed B cells
- describe CD22+ isolation and activation of CD22+ B cells
- isolate CD22+ B cells
- isolate IgG+ B cells
- prepare irradiated feeder cells
- immortalize B cells with EBV
- clone B cells
- prepare irradiated B-cell depleted feeder cells
- screen B cell supernatant for binding to RSV F protein
- extract RNA from B cells
- synthesize cDNA from RNA
- amplify IgG heavy chain and light chain genes by PCR
- link heavy and light chain genes into a single cassette
- introduce diagnostic uses
- describe PCR II: kappa light chain
- describe PCR II: heavy chain
- describe overlap PCR
- describe digestion with Sfi and cloning into pCAL expression vector
- describe transformation into E. coli
- summarize diagnostic uses
- introduce isolation of anti-RSV Fab antibodies
- describe B cell isolation
- describe single cell sorting
- describe first strand cDNA synthesis
- describe IgG heavy chain and kappa light chain amplification
- describe step I amplification
- describe step II amplification
- describe step III overlap PCR
- describe step IV introduction of CH1 region
- describe step V digestion with Sfi and cloning into pCAL expression vector
- describe diagnostic uses
- select individual colonies
- perform ELISA for antibody binding
- test Fab antibodies for RSV F1 lysate binding
- confirm Fab production and RSV F1 lysate binding
- sequence positive binders
- express and purify isolated Fabs
- reconfirm binding of purified Fabs to RSV F lysate
- test purified Fabs for RSV neutralization
- measure binding of Fabs to RSV F protein
- determine EC50s for binding of Fabs
- perform RSV neutralization assay
- analyze anti-RSV antibodies for neutralization
- calculate ED50 and plaque reduction rate
- summarize results of RSV neutralization assay
- present diagnostic uses
- describe neutralization assay results
- clone and express IgG
- describe IgG binding assays
- describe IgG RSV neutralization assays
- neutralize RSV monoclonal antibody resistant RSV escape mutants
- perform competition assays
- describe competition assay results
- generate RSV MARMs
- analyze neutralization of RSV MARMs
- describe MARM generation for motavizumab
- describe MARM generation for 58C5
- describe MARM generation for 30D8
- summarize neutralization assays
- describe neutralization of RSV A2 parental virus
- describe neutralization of motavizumab MARM
- describe neutralization of 58C5 MARM
- map 58C5 binding epitope
- describe screening of RSV F protein mutant library
- identify residues involved in 58C5 binding
- map 30D8 binding epitope
- identify residues involved in 30D8 binding
- conclude epitope mapping results

